ProcartaPlex™ Human Arteriosclerosis Panel, 5plex (Invitrogen™)

TheProcartaPlex Human Arteriosclerosis Panel 5plex enables cardiovascular research by analyzing 5 protein targets: BMP-2, COMP, FGF-23, osteoprotegerin, and RANKL in a single well using Luminex xMAP technology. Arteriosclerosis is a stage of thickening, hardening, and loss of elasticity and compliance of arterial walls and may lead to atherosclerosis (buildup of fatty plaques on the artery walls). Simultaneous detection of these targets can help explore diseases such as coronary artery disease. The panel is provided in a ready-to-use format with individual vials of capture and detection reagents formulated at 1X concentration, requiring less pipetting and experimental setup. It is not combinable with simplexes or other panels. It complements the Human Atherosclerosis Panel 1 9plex (Cat. No. EPX090-15822-901) and Human Atherosclerosis Panel 2 4plex (Cat. No. EPX040-15824-901) providing 13 additional protein targets in the same research area.

ProcartaPlex preconfigured panels are extensively tested for analyte combinability, interference, and cross-reactivity to provide the highest level of validation and precision. All ProcartaPlex panels are supplied with the necessary reagents to perform the assay.

Target list [bead region]: BMP-2 [56], COMP [64], FGF-23 [54], Osteoprotegerin (OPG) [19], RANKL [46]

About ProcartaPlex assays for the Luminex platform
ProcartaPlex immunoassays are based on the principles of a sandwich ELISA, using two highly specific antibodies binding to different epitopes of one protein to quantitate all protein targets simultaneously using a Luminex instrument. ProcartaPlex multiplex assays require as little as 25 μL of plasma or serum, or 50 μL of cell culture supernatant, and just four hours to obtain analyzed results.

Features include:
• Reproducible, reliable results—validated as a panel to the highest industry standard, including protein target combinability and cross-reactivity testing
• More results per sample—measure multiple protein targets simultaneously in a single 25–50 μL sample
• Well-established Luminex technology highly referenced multiplexing platform for protein detection and quantitation

ProcartaPlex assays utilize Luminex xMAP (multianalyte profiling) technology for the simultaneous detection and quantitation of up to 80 protein targets in a single 25–50 μL sample—from plasma, serum, cell culture supernatants, and other bodily fluids.

The Luminex beads in the ProcartaPlex assay are internally dyed with precise proportions of red and infrared fluorophores to create spectrally unique signatures that can be identified by the Luminex xMAP detection systems (e.g., Luminex 200, FLEXMAP 3D, and MAGPIX). Similar to a sandwich ELISA, the ProcartaPlex assay uses matched antibody pairs to identify the protein of interest. In a multiplexed assay, each spectrally unique bead is labeled with antibodies specific for a single target protein, and bound proteins are identified with biotinylated antibodies and streptavidin–R-phycoerythrin (RPE). The conjugation of protein-specific antibodies to a distinct bead allows for analysis of multiple targets in a single well.